Alamar Biosciences, Inc.
ALMR
$29.36
-$0.60-1.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 29.43M | 26.04M | 16.16M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 29.43M | 26.04M | 16.16M | ||
| Cost of Revenue | 11.71M | 11.58M | 7.58M | ||
| Gross Profit | 17.72M | 14.46M | 8.58M | ||
| SG&A Expenses | 17.43M | 13.79M | 7.61M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 42.96M | 38.38M | 24.08M | ||
| Operating Income | -13.53M | -12.35M | -7.92M | ||
| Income Before Tax | -13.29M | -20.86M | -7.02M | ||
| Income Tax Expenses | -93.00K | 464.00K | -- | ||
| Earnings from Continuing Operations | -13.20M | -21.33M | -7.02M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -13.20M | -21.33M | -7.02M | ||
| EBIT | -13.53M | -12.35M | -7.92M | ||
| EBITDA | -12.40M | -11.18M | -7.00M | ||
| EPS Basic | -0.23 | -1.74 | -0.62 | ||
| Normalized Basic EPS | -0.13 | -0.63 | -0.38 | ||
| EPS Diluted | -0.23 | -1.74 | -0.62 | ||
| Normalized Diluted EPS | -0.13 | -0.63 | -0.38 | ||
| Average Basic Shares Outstanding | 58.67M | 12.26M | 11.41M | ||
| Average Diluted Shares Outstanding | 58.67M | 12.26M | 11.41M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||